Press releases


INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

NIOX GROUP PLC (formerly Circassia Group plc) (“NIOX” or the “Company” and, together with its subsidiaries, the Group“) Oxford, UK – 14 September 2022: NIOX Group plc (LSE: NIOX), a company engaged in the design, development, and commercialisation of medical devices for asthma

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021

Oxford, UK – 22 March 2022: Circassia Group plc (“Circassia” or “the Group”; AIM: CIR), a medical device company focused on point of care asthma diagnosis and management, today announces its audited results for the year ended 31 December 2021.

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021

Oxford, UK – 16 September 2021: Circassia Group plc (LSE: CIR), a medical device company focused on point of care asthma diagnosis and management, today announces its unaudited interim results for the six months ended 30 June 2021 (“H1 2021”).

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020

Oxford, UK – 24 March 2021: Circassia Group plc (“Circassia” or the “Company” and, together with its subsidiaries, the “Group”) (LSE: CIR) today announces its audited results for the year ended 31 December 2020 and a post-period update. Financial highlights

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020

Oxford, UK – 17 September 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR), a leading medical device business focused on respiratory disease, today announces its unaudited interim results for the six months ended 30 June 2020. Financial highlights

CIRCASSIA GROUP PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019

Oxford, UK – 16 June 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR) today announces its preliminary results for the year ended 31 December 2019 and a post-period update. Financial progress Key performance indicators £m 2019 underlying continuing

Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interest

The information contained within this announcement is deemed by Circassia Pharmaceuticals plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information

Circassia Announces Business Update

Oxford, UK – 9 January 2020: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces a business update including a trading update for the year ended 31 December 2019. Unaudited

Update on Circassia’s Licensing Agreement with BeyondAir Inc. for LungFit PH

Oxford, UK – 19 December 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, provides an update on its licensing agreement with BeyondAir Inc. (previously AIT Therapeutics Inc.) for the commercial

Circassia Announces Board Changes

Oxford, UK – 5 December 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces a number of changes to its Board and Executive Management. Chief Executive Officer Circassia announces

Circassia Announces Duaklir® US Launch at American College of Chest Physicians’ CHEST Annual Meeting 2019

– Duaklir® launch expands Circassia’s US portfolio of COPD products alongside Tudorza® – Oxford, UK and Morrisville, NC, United States – 21 October 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory

Interim results for the six months ended 30 June 2019

Oxford, UK – 26 September 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its unaudited interim results for the six months ended 30 June 2019 and a post-period

Circassia Appoints Industry Veteran Jonathan Emms as Chief Operating Officer

– COO to join Board and SVP R&D to step down as Director reflecting Company’s commercial focus – Oxford, UK – 12 August 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory

Circassia Announces Publication of Tudorza® Phase IV ASCENT Study in the Journal of the American Medical Association

Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of

Preliminary Results for the Year Ended 31 December 2018

Oxford, UK – 1 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its preliminary results for the year ended 31 December 2018 and a post-period update. Financial

Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease

– Duaklir® launch planned H2 2019 – – Duaklir® to join Tudorza® in Circassia’s portfolio of US COPD products – Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused

Circassia Announces FDA Approval of Tudorza® Supplemental New Drug Application

This announcement contains inside information for purposes of Article 7 of Market Abuse Regulation 596/2014 Click here to download the full press release – Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added

Admission to AIM

Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR),a specialty pharmaceutical company focused on respiratory disease, today announces that further tothe Company’s announcement on 10 December 2018 and the General Meeting on 4 January

Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza® from AstraZeneca

Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has issued a notice of option exercise to AstraZeneca to acquire the full US

Interim Results for the Six Months Ended 30 June 2018

– NIOX® sales growth continued – – Tudorza® profit share revenues increased – – Duaklir® NDA and Tudorza® sNDA accepted for review by FDA – – China commercial expansion on track – – AstraZeneca equity stake increased – Oxford, UK

Circassia Announces Duaklir® New Drug Application (NDA) and Tudorza® Supplemental NDA Accepted for Review by FDA

– PDUFA target action date of 31 March 2019 confirmed for both filings – Oxford, UK – 13 August 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that the

Circassia Announces Submission of Duaklir® New Drug Application and Tudorza® Supplemental New Drug Application in the United States

– Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) – – Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label – Oxford, UK – 1 June 2018: Circassia Pharmaceuticals plc (“Circassia” or “the

Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza® Phase IV and Duaklir® Phase III Studies

Oxford, UK – 22 May 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® Pressair® phase IV ASCENT study and

Preliminary Results for the Year Ended 31 December 2017

– Strong NIOX® sales growth – – Good progress in AstraZeneca US commercial partnership – – Compelling clinical data for Tudorza® and Duaklir® – – Commercial platform expansion in US and China – – Refocused investment strategy to support commercial

Circassia Receives Innovative Technology Contract from Vizient, Inc. for NIOX VERO® Asthma Management Products

Oxford, UK – 8 February 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that it has received a multi-year Innovative Technology contract for its NIOX VERO® asthma management

Circassia Announces Tudorza® Successfully Met Both Primary Endpoints in ASCENT Phase IV Study in Chronic Obstructive Pulmonary Disease

– Significantly reduced COPD exacerbations – – Demonstrated favourable cardiovascular safety profile similar to placebo – – Circassia’s partner AstraZeneca plans to file data for inclusion in US label – Oxford, UK – 4 December 2017: Circassia Pharmaceuticals plc (“Circassia”

Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis

Oxford, UK – 29 November 2017: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, welcomes the publication of new clinical guidelines by the UK’s National Institute for Health and Care Excellence

Interim Results for the Six Months Ended 30 June 2017

– Strong NIOX® sales growth – – Duaklir® NDA filing on track following positive phase III results – – AstraZeneca US commercial collaboration progressing well – – Respiratory pipeline advancing – Oxford, UK – 27 September 2017: Circassia Pharmaceuticals plc

Circassia Announces European Launch of NIOX VERO® Nasal Mode for Screening of Primary Ciliary Dyskinesia

Oxford, UK – 12 September 2017: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the European launch of the NIOX VERO® nasal application for the screening of primary ciliary

Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease

– NDA submission planned H1 2018 by partner AstraZeneca – – Filing supported by positive results from ACHIEVE dose-ranging study – – Circassia has exclusive commercialisation rights to Duaklir® in the United States – Oxford, UK – 7 September 2017:

Preliminary Results for the Year Ended 31 December 2016

– Transformational transaction with AstraZeneca for US commercial rights to two COPD products – – Leverages commercial infrastructure established as key growth platform – – Robust NIOX® sales growth – – Broad respiratory pipeline progressing – – Allergy investment halted

Circassia Announces Top-Line Results from House Dust Mite Allergy Field Study

– Primary endpoint not achieved – – Treatment groups had greatly reduced Combined Score and symptoms – – Strong placebo effect mirrored previous cat allergy study – – Allergy investment halted – – Circassia to focus on broader respiratory business

Completion of the Transaction and admission to trading on the London Stock Exchange

12 April 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY

Proposed Collaboration and Securing of Certain U.S. Commercial Rights to Tudorza® and Duaklir® from AstraZeneca

17 March 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY

Interim Results for the Six Months Ended 30 June 2016

– Strong NIOX® sales growth; respiratory pipeline progressing – – Unexpected phase III allergy results; Spring 2017 house dust mite results will inform allergy approach – – Commercial infrastructure expanded as strategic growth platform – – Robust portfolio strategy; early

Circassia Announces Top-Line Results from Cat Allergy Phase III Study

– Primary endpoint not achieved – – Treatment groups had dramatically reduced Combined Score and symptoms – – Powerful placebo response eliminated ability to identify treatment effect – – Wider NIOX® and respiratory franchises unaffected by results – Oxford, UK

Preliminary Results for the Year Ended 31 December 2015

– Positioned to deliver – – Cat allergy phase III study on track to report Q2 2016 – – Acquisitions validated; strong NIOX® sales growth and lead asthma product approved – – Fully funded; successful £275 million fundraising completed June

Circassia Announces Positive Outcome of European Decentralised Procedure for Approval of Its Fluticasone Propionate Equivalent of GSK’s FLIXOTIDE® pMDI

– Product approvable in all reference product strengths – – Successful application based on in vitro demonstration of therapeutic equivalence – Oxford, UK – 24 November 2015: Circassia Pharmaceuticals plc (LSE: CIR) today announces the positive outcome of the European

Circassia Business Update

— Good clinical progress across whole allergy and respiratory portfolio — — Strong commercial progress with significant NIOX® sales growth — — Robust balance sheet to fund delivery of pipeline — Oxford, UK – 27 October 2015: Circassia Pharmaceuticals plc

Interim Results for the Six Months Ended 30 June 2015

– Clinical programs on track – – Cat allergy phase III to report H1 2016; recruitment for grass allergy phase III to start H1 2016 – – Acquisitions accelerate commercialization strategy and broaden portfolio – – Successful £275 million fundraising

Circassia’s Extended Offer Period for Aerocrine has Increased Acceptances to 97.2 Percent

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA EXCEPT IN CERTAIN

Completion of Acquisition of Prosonix Limited

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA EXCEPT IN CERTAIN

Proposed Acquisitions of Aerocrine AB and Prosonix Limited Creating a World-Class Allergy and Asthma Specialty Pharma Business

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA,

Preliminary Results for the Year Ended 31 December 2014

– Strong clinical progress; Cat-SPIRE phase III study fully recruited – – Robust financial position; fully-funded to bring Cat-SPIRE to market – – Commercialisation preparations underway; infrastructure build advancing – Oxford, UK – 26 February 2015: Circassia Pharmaceuticals plc (“Circassia”

Circassia Interim Management Statement

– Strong operational progress; clinical programmes on track – – Encouraging results from third season follow-up study in grass allergy – Oxford, UK – 11 November 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company

Interim Results for the Six Months Ended 30 June 2014

— Successfully raised over £200 million in landmark IPO — — Fully-funded to bring to market the first of a new generation of allergy immunotherapies — — Strong operational momentum and Cat-SPIRE phase III study >85% recruited — Oxford, UK

Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study

Oxford, UK – 13 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today announces positive top-line results from a two-year follow-up of a phase IIb clinical study of HDM-SPIRE, a house dust

Notice of Interim Results

Oxford, UK – 3 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2014 on Tuesday 29 July 2014. An

Interim management statement

Oxford, UK – 19 May 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 18 May 2014. OPERATIONAL HIGHLIGHTS Cat-SPIRE •

Admission to trading on the London Stock Exchange

NOT INTENDED TO PROMOTE THE SALE OF ANY SECURITIES, AND NOT FOR PUBLICATION,DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTOTHE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THEUNITED STATES AND THE